anti-glypican-2 CAR T-cell therapy (Childrens Hospital of Philadelphia/Kite Pharma)

N/A

Report date: 2026/03/06 20:02:51

Base Information

Drug Nameanti-glypican-2 CAR T-cell therapy (Childrens Hospital of Philadelphia/Kite Pharma)
Drug Alias Nameanti-glypican-2 CAR T-cell therapy (Childrens Hospital of Philadelphia/Tmunity)GPC2 CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlypican-2 modulators
TargetsGlypican-2
Therapy Area/IndicationsCNS Embryonal TumorUrinary Bladder NeoplasmsSmall Cell Lung Carcinoma +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChildrens Hospital of Philadelphia
China Registration ClassN/A

Develop Information

Active CompaniesChildrens Hospital of PhiladelphiaStanford UniversityKite Pharma Inc
Inactive CompaniesTmunity Therapeutics Inc
Active IndicationsCNS Embryonal TumorUrinary Bladder NeoplasmsSmall Cell Lung Carcinoma +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A